FIELD: medicine.
SUBSTANCE: invention relates to the field of medicine and is used in gastroenterology. In the blood serum, the activity of AsAT, the plasma content of the intercellular adhesion molecule-1 (ICAM-1) and P-selectin are determined, followed by calculating the risk of the presence or absence of non-alcoholic steatohepatitis in the patient.
EFFECT: method allows for an increase in the sensitivity, specificity and accuracy of the study.
1 cl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING SEVERE HEPATIC FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2021 |
|
RU2765847C1 |
| METHOD OF EARLY DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2022 |
|
RU2798723C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN FEMALES | 2020 |
|
RU2744021C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN MEN | 2020 |
|
RU2753455C1 |
| METHOD FOR PREDICTION OF PROGRESSIVE CLINICAL COURSE OF EARLY FORMS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2020 |
|
RU2768466C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND TYPE 2 DIABETES MELLITUS | 2018 |
|
RU2706026C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| METHOD OF DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN METABOLIC SYNDROME | 2022 |
|
RU2803945C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE | 2013 |
|
RU2537229C1 |
| METHOD FOR PREDICTION OF HEPATOTROPHIC THERAPY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE | 2015 |
|
RU2595827C1 |
